Fig. 1.

Effects of NFAT inhibitor on cardiac hypertrophy-induced by potassium bromate (KBrO3). (A) The hypertrophic response of H9c2 cells enhanced by KBrO3 is dose-dependently reversed by NFAT inhibitor at indicated concentration. (B) Change in fluorescent intensity was depicted as fold difference over. The mRNA levels of the biomarkers for cardiac hypertrophy, either (C) atrial natriuretic peptides (ANP) or (D) brain/B-type natriuretic peptides (BNP), were also compared. n = 6, *P < 0.05 and **P < 0.01 vs. normal control (first column). ^#P < 0.05 vs. samples treated with NFAT inhibitor at high dose (last column).